International Journal of Pharmaceutical Compounding

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

PreScription: First Estriol, Then What?

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2008 - Hormone Replacement Therapy
View All Articles in Issue

Page(s): 284

PreScription: First Estriol, Then What? Page 1

Download in electronic PDF format for $75

Abstract:

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, U.S. Food and Drug Administration, FDA, estriol, regulation, Wyeth, hormone replacement therapy, drug safety

Related Categories: HRT, LEGAL, ADVERSE DRUG EVENTS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
PreScription: First Estriol, Then What? Allen Loyd V Jr	Jul/Aug 2008 Pg. 284
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
The Science Behind Hormone Replacement Therapy, Part 1 Wepfer Scott T	Nov/Dec 2001 Pg. 462-464
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr	Nov/Dec 2003 Pg. 449-450
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
Estriol: Women's Choice vs. A Manufacturer's Greed Goodrum Jennifer	Jul/Aug 2008 Pg. 286-292
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 Allen Loyd V Jr	Jul/Aug 2007 Pg. 350-351
The Politics of Hormone Replacement Therapy Allen Loyd V Jr	Jul/Aug 2007 Pg. 278-281
Documentation: Records and Reports Akers Michael J	Sep/Oct 2017 Pg. 373-380
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Allen Loyd V Jr, Ashworth Lisa D	Jan/Feb 2005 Pg. 44-46
Return to Top